Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper

Dieser Humanized Monoklonal Antikörper erkennt spezifisch Trop2 (Sacituzumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7795133
-15% Promotion 2026
771,54 €
907,69 €
Sparen Sie 136,15 € (-15 %)
Zzgl. Versandkosten 20,00 € und MwSt
5 mg
Lieferung nach: Deutschland
Lieferung in 10 bis 13 Werktagen

Kurzübersicht für Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper (ABIN7795133)

Target

Trop2 (Sacituzumab Biosimilar)

Antikörpertyp

Recombinant Antibody

Reaktivität

Human

Wirt

  • 4
  • 1
Humanized

Klonalität

  • 4
  • 1
Monoklonal

Konjugat

  • 4
  • 1
Dieser Trop2 (Sacituzumab Biosimilar) Antikörper ist unkonjugiert

Applikation

  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse

Research Grade
  • Expressionssystem

    Mammalian cells

    Verwendungszweck

    Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg

    Produktmerkmale

    What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

    Aufreinigung

    Protein A or G affinity column

    Reinheit

    >95 % by reducing SDS-PAGE

    Endotoxin-Niveau

    Less than 0.5 EU/mg of protein as determined by LAL method

    Immunogen

    Human Trop-2
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    > 3 mg/mL

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Target

    Trop2 (Sacituzumab Biosimilar)

    Andere Bezeichnung

    Sacituzumab Biosimilar

    Substanzklasse

    Biosimilar
Sie sind hier:
Chat with us!